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Abstract 
Chemical cross-linking of protein crystals form an insoluble and active protein matrix. 
Cross-linked protein crystals (CLPCs) have many excellent properties including high 
volumetric activity and stability. In this thesis CLPC technology was studied in 
bioseparation and biocatalytic applications. 
A novel immunoaffinity separation material, cross-linked antibody crystals (CLAC), was 
developed in this thesis for enantiospecific separation of a chiral drug, finrozole. 
Previously, the preparation of an antibody Fab fragment ENA5His capable of 
enantiospecific affinity separation of the chiral drug has been described. However, in a 
carrier-immobilized form ENA5His suffered from poor stability in the presence of a high 
concentration of organic solvents needed to release the bound drug. In this study 
crystallization conditions for ENA5His were found by means of small-scale vapor 
diffusion experiments. Crystallization was further scaled up to 10 ml batch crystallization 
with a 70% protein yield. Glutaraldehyde cross-linking modified the ENA5His crystals 
into an insoluble form producing a CLAC matrix. The CLAC matrix packed in a column 
separated pure enantiomers from the racemic mixture of the drug. The CLAC matrix was 
totally stable at the elution conditions enabling reuse of the immunoaffinity column. 
However, the specific drug enantiomer binding capacity of CLAC was only 50% of the 
corresponding capacity of carrier-immobilized ENA5His. Also a cross-linked carrier-
immobilized ENA5His column was prepared to study the effect of  bare chemical cross-
linking. Surprisingly, the cross-linked immobilized ENA5His was as active as the native 
immobilized ENA5His and simultaneously stable against the denaturing effect of 
methanol.  
Xylose isomerase (XI) is a widely used enzyme in industry as a result of its ability to 
catalyze isomerization of D-glucose to D-fructose. Previously it has been shown that XI 
accepts all of the pentose sugars and many hexose sugars as isomerization substrates. In 
the present study novel tetrose isomerizations and C-2 epimerizations with both the D- 
and L-forms of the sugars by an industrial xylose isomerase (XI) from Streptomyces 
rubiginosus were described. Furthermore, the results showed that the real equilibrium of 
XI catalyzed reactions is not between two isomers but between a ketose and its two 
aldose isomers. These findings together with previous results show that XI can be used as 
a catalyst for production of a variety of sugars. 
Obtaining homogeneous enzyme crystals is critical to their application as catalysts in a 
cross-linked form. In this study a method for the production of homogeneous crystals of 
XI was developed. Firstly, the XI crystal solubility was measured with respect to 
precipitant salt concentration, temperature, and pH. Secondly, based on the results of the 
solubility study, a process for the production of uniform XI crystals of different size 
classes was developed. Crystals with average crystal sizes between 12 µm and 360 µm 
were produced. XI crystals were further cross-linked by glutaraldehyde and L-lysine to 
prepare insoluble cross-linked xylose isomerase crystals (CLXIC). 
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The cross-linking of XI crystals improved their stability towards organic solvents. This 
can be exploited in the production of D-fructose and possibly also other sugars. Adding 
acetone to the reaction mixture enhanced the production of D-fructose from D-glucose 
catalyzed by CLXIC in terms of product yield and reaction rate. The D-fructose 
equilibrium concentration increased from 49% to 64% when increasing the acetone 
concentration from 0% to 90% in the reaction mixture at 50 °C. In 50% acetone the 
fructose production rate was more than doubled compared with that in a pure buffer 
solvent. Acetone seems to have only a minor role in the inactivation of cross-linked 
crystals. The residual activity of CLXIC was 70–80% of the initial activity after a 24-h 
incubation at 50 oC in a buffer solution (pH 7.2) containing 10–90% acetone. In the 
soluble form, the activity of XI decreased by 75% after incubation in 50% acetone for 24 
h at 50 °C. 
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Abbreviations 
CLPC  Cross-linked protein crystal 
CLAC  Cross-linked antibody fragment ENA5His crystal 
CLXIC Cross-linked xylose isomerase crystal 
De  Effective diffusivity 
DMF  N,N-dimethylformamide 
DMSO  Trimethyl sulfoxide 
DPDPB 1,4-di-[3’-(2’-pyridyldithio)propionamido]butane 
GC  Gas chromatography 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HLADH Horse liver alcohol dehydrogenase 
HPLC  High performance liquid chromatography 
kDa  Kilodalton 
MβCD  Methyl-β-cyclodextrin 
MPD  2-methyl-2,4-pentane-diol 
MW  Molecular weight 
MWCO Molecular weight cut-off 
NADH  Reduced nicotinamide adenine dinucleotide 
PBS  Phosphate buffered saline 
PEG  Polyethyleneglycol 
PMSF  Phenylmethylsulfonylfluoride 
R  Radius of spherical catalyst particle 
ractual  Actual reaction rate 
rideal  Ideal reaction rate 
Sc-fluids Supercritical fluids 
TAME  Tosyl-L-arginine methylester 
THF  Tetrahydrofuran 
Tris  Tris(hydroxymethyl)aminomethane 
XI  Xylose isomerase 
Å  Ångström, 10-10 m 
εmax   Maximum energy dissipation rate 
Φ  Thiele modulus 
η  Effectiveness factor 
ρc  Density of catalyst 
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1 Introduction 
Enzymes catalyze virtually all reactions in biological systems. They are highly active and 
specific catalysts. The specificity is the result of the active site in enzymes, which 
specifically binds the substrate that has a precise size and shape that only fits to the active 
site. The active site in enzymes can even distinguish between optical isomers and 
enantiotopic groups of chiral or prochiral molecules. There is a growing interest in 
application of proteins as catalysts in fine chemical production, as biosensors, as 
pharmaceuticals, and in food and detergent applications. Lalonde summarized [1] the 
main advantages in using enzymes in practical applications: they are highly selective, 
they are efficient, they work under ambient conditions at neutral pH, they are 
environmentally benign, a broad range of reactions are possible, and they are  “green” 
catalysts producing less waste and consuming less energy. However, there are drawbacks 
in enzyme-catalyzed reactions. They can exhibit a slow reaction rate, they can be 
unstable in practical operational conditions, the storage stability can be poor, the 
downstream processing can be complex, the scale-up of enzymatic processes is often 
difficult, and the bulk supply of proteins is often limited [1, 2]. The slow reaction rate can 
be a result of the addition of organic solvents or reagents in the reaction mixture or the 
inhibition of enzymes at high concentrations of substrates or products, for example. 
Enzyme catalysts are inactivated by a variety of commonly encountered process 
conditions, including organic solvents, proteolysis, elevated temperatures, and a high 
concentration of organic reagents. Moreover, biocatalysts are commonly used as impure 
water-soluble protein preparations that contain only a small fraction of the active catalyst 
(usually 0.5–10%). In catalysis it is even possible that more catalyst is added than 
reactant [3]! 
The properties of enzymes have been improved by protein engineering or by 
immobilization, for example. Protein engineering can be used in order to enhance both 
stability and activity. However, protein engineering is laborious and only one property of 
one protein can be altered at one time. Furthermore, expression systems and an 
economically viable production process have to be developed for the new protein. 
Enzyme immobilization is used to facilitate the down-stream processing and to improve 
the stability of enzymes. Immobilized enzymes can be easily removed from the reaction 
mixture and, thus, can be recycled and reused. However, the stability enhancement is 
usually negligible. Moreover, the use of an inert solid support leads to a low overall 
activity of an immobilized protein matrix.  
Chemical cross-linking of enzyme crystals was first developed in the 1960’s to stabilize 
enzyme crystals in order to facilitate the manipulation and the collection of 
crystallographic data by X-ray crystallography [4]. However, it was soon recognized that 
cross-linked crystalline enzymes were catalytically active [5]. Cross-linked enzyme 
crystals, or more generally cross-linked protein crystals (CLPCs) are created by 
crystallization of protein followed by a chemical cross-linking that “locks” the crystalline 
state outside the crystallization conditions. CLPCs form an active, insoluble, 
mechanically robust, and microporous protein matrix. CLPCs have been used as catalysts 
in various enzymatic production processes, as separation matrices, and in some other 
applications. However, the development of CLPC technology is still under way and the 
number of proteins commercially available as cross-linked crystals is very limited. 
Protein crystallization and CLPC technology are described below in greater detail. 
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1.1 Crystallization of proteins 
A solution system remains at equilibrium until the point is reached where there is 
insufficient solvent to maintain full hydration of the solute molecules. If more solute is 
added to the solution, the system is no longer at equilibrium under this so-called 
supersaturated state. The system will be thermodynamically driven toward a new 
equilibrium corresponding free energy minimum by forming a solid phase. The solid 
phase can appear as either amorphous precipitate or crystals. The principle of 
crystallization is similar for small molecules (e.g., salts and small organic compounds) 
and macromolecules (e.g., proteins, DNA, and RNA). Three stages are common to all 
crystallizations: nucleation, crystal growth, and cessation of crystal growth. In nucleation 
molecules or non-crystalline aggregates (dimers, trimers, etc.) produce a stable aggregate 
with a repeating structure. The nucleus must first exceed a specific size, called the critical 
size, before it is capable of further growth. However, the formation of crystal nuclei from 
supersaturated solution does not necessarily result in the subsequent formation of 
macroscopic crystals. Cessation of crystal growth can occur for many reasons. The most 
obvious reason is that the equilibrium between the crystalline and soluble form is 
achieved.  
The crystallization of proteins is usually more difficult than small molecule 
crystallization. This is probably a result of the difficulty to obtain a high quality protein 
sample for crystallization. Because precise protein–protein contacts are needed for the 
crystallization of proteins, any factor that introduce heterogeneity into the protein sample 
may have interfering effects on the crystallization. There are numerous factors that can 
introduce heterogeneity into a protein sample including differential glycosylation on the 
protein molecules, different conformations of the protein can be present, contamination 
in the form of other proteins, protein denaturation, and protein degradation [6]. 
The basic strategy to crystallize proteins is to bring the system into a state of limited 
degree of supersaturation. This can be done, for example, by removing the solvent, 
adding a precipitating agent, or by altering some physical properties such as temperature. 
However, there are dozens of other parameters that are involved in protein crystallization 
[6]. Protein crystallization is presented in detail in numerous handbooks (e.g., [6, 7]). 
1.2 Applications of protein crystallization 
1.2.1 Structure determination 
Protein crystallization is mainly used for structure determination by X-ray 
crystallography where large, high quality crystals are needed. Obtaining high quality 
diffractive crystals is the bottleneck in protein structure determination. For structure 
determination purposes protein crystals are most often crystallized by small-scale 
microdiffusion methods (for a review of these methods, see Refs [6, 7]). Very often 
crystallization conditions are found after setting up hundreds or thousands of individual 
crystallization conditions employing the “trial and error” approach, as crystallization is 
often considered as a necessary evil in the structure determination work.  
The structural analysis is based on the principle that in a perfect crystal all the molecules 
have the same conformation and orientation.  When X-rays are focused through protein 
(or any other pure substance) crystal, individual atoms diffract the rays. The number of 
electrons in each atom determines the intensity of the scattering of X-rays and, thus, the 
X-rays striking particular atoms will all be diffracted in the same way. A diffraction 
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pattern is generated by the interference of individual X-rays. A series of diffraction 
patterns are taken from several angles and these patterns represent the way atoms are 
arranged in the molecule and can be used to determine the structure of the protein. There 
are currently more than 18000 protein structures in the Protein Data Bank (PDB) [8], 
which have been determined by X-ray diffraction analysis. 
1.2.2 Protein purification 
Crystallization is an efficient protein purification method. However, purification by 
crystallization is relatively rare even though the quality of the crystals is not crucial. 
Chromatographic methods have replaced protein crystallization in protein purification 
although the latter was commonly used earlier. However, protein purification by 
crystallization has many advantages: high yield, high purity in one step, unlimited scale-
up possibilities, and the product is a highly concentrated protein crystal slurry ready for 
further formulation. Some industrial proteins, like xylose isomerase (EC 5.3.1.5) [9], 
cellulase (EC 3.2.1.4) [10], and protease (EC 3.4.-.-.) [11], have been purified by 
crystallization in large-scale. 
1.2.3 Medical applications 
A majority of small molecular weight drugs are produced in crystalline form because of 
the high storage stability, purity, and reproducibility of the drug properties [12]. There 
are hundreds of macromolecular therapeutic agents used in clinical trials or approved as 
drugs [13]. However, only insulin is produced and administered in a crystalline form 
[14]. According to Margolin and Navia [15] the crystallization of macromolecular 
pharmaceuticals can offer significant advantages, such as: a) protein purification by 
crystallization as presented above; b) high stability of the protein product compared with 
soluble or amorphous forms; c) crystals are the most concentrated form of proteins, 
which is a benefit for storage, formulation, and for drugs that are needed in high doses 
(e.g., antibiotics); d) the rate of crystal dissolution depends on the morphology, size, and 
additives; thus, crystalline proteins may be used as a carrier-free dosage form. 
1.2.4 Cross-linked protein crystals (CLPCs) 
In many applications crystallized proteins are not suitable for use as such as a result of 
their fragility and solubility. In order to produce a crystalline protein matrix that is 
insoluble also in other conditions than those used in crystallization, the crystals have to 
be chemically cross-linked. In general, chemical cross-linking of protein crystals creates 
an active and microporous protein matrix that can be used in catalytic and separation 
applications. 
1.3 Chemical cross-linking of protein crystals 
1.3.1  Glutaraldehyde 
Protein crystals dissolve in other conditions than those used in the crystallization. 
Chemical cross-linking of protein crystals “locks” the crystalline state and, thus, the 
cross-linked protein crystals are insoluble also outside the conditions that initially led to 
crystallization. The most commonly used cross-linking reagent is a bifunctional 
aldehyde, glutaraldehyde. Most often, the cross-linking reaction is carried out near 
neutral pH by adding 0.1–2% (w/v) glutaraldehyde to the crystallization mother liquor 
containing the native protein crystals. This mixture is then incubated in cool conditions 
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(0–25 °C) for 0.5–2 h. The resulting chemical cross-linking takes place throughout the 
crystalline lattice and is intermolecular but intracrystalline. 
It is well established that glutaraldehyde reacts with the free ε-amino groups of lysine 
residues in proteins. In numerous studies the amino acid composition of cross-linked 
protein crystals has been analyzed and it was clearly shown that only lysine residues of 
proteins reacted in the cross-linking reaction by glutaraldehyde [5, 16, 17, 18]. As an 
exception, an amino acid analysis of cross-linked chloroperoxidase (EC 1.11.1.10) 
crystals suggested that also serines and arginines were modified in the glutaraldehyde 
cross-linking reaction [19]. Crystallographic studies show that glutaraldehyde cross-
linking reaction had only minor effects on the structure of lysozyme (EC 3.2.1.17)  [20], 
carboxypeptidase A (EC 3.4.17.1) [4], subtilisin (EC 3.4.21.62) [21], an N-cadherin 
fragment [22], and a gp120 ternary complex [22].  The X-ray crystallographic data from 
triclinic lysozyme crystals indicate that only lysine residues were modified in 
glutaraldehyde cross-linking [20].  
In principle, the carbonyl function in aldehydes reacts with free amino groups and the 
reaction product is a Schiff base. A general characteristic of Shiff bases is that they are 
readily hydrolyzed in acidic conditions. However, numerous examples show that the 
cross-linking reaction between glutaraldehyde and proteins is irreversible, shown by 
incubating cross-linked protein crystals in acidic solution [23], for example. This rules 
out a simple Shiff base formation. 
Glutaraldehyde is known to form polymers in solution [24, 25, 26]. It is speculated that 
the ability of glutaraldehyde to stabilize protein crystals stems from the fact that in 
aqueous solution glutaraldehyde forms a mixture of oligomers of different lengths and 
structures [27], and therefore the most appropriate cross-linking species reacts with 
crystalline protein [17]. At acidic pH, the oligomers are cyclic hemiacetals (Figure 1a) 
[25, 26] that form Shiff bases in analogy with the mechanism of Cordes and Jencks [28]. 
At neutral or slightly alkaline pH, where protein cross-linking is carried out, α,β-
unsaturated glutaraldehyde polymers are formed (Figure 1b) [25, 26]. Basing his 
conclusions on earlier studies [24, 29], Wong [30] proposed a reaction mechanism where 
the unsaturated glutaraldehyde polymer cross-links the amino groups (lysine residues) of 
proteins as shown in Figure 1b. Rydon and co-workers have proposed a different reaction 
mechanism, where glutaraldehyde cross-linking of proteins leads mainly to formation of 
stable quaternary pyridinium compounds [25, 26]. As a conclusion, the mechanism of 
glutaraldehyde cross-linking of proteins is not fully understood.  
Visuri [31] showed in his patent that glutaraldehyde cross-linking alone didn’t provide 
insolubility of xylose isomerase (XI) crystals. However, when an amino group containing 
compound was added to the cross-linking reaction mixture, the resulting cross-linked XI 
crystals were insoluble. Visuri used ammonium salts, amines, and amino acids as the 
source of the additional amino groups. The reason for the improved cross-linking in the 
presence of exogenous amino groups remained unknown.  
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Figure 1. Polymerization of glutaraldehyde at a) acidic pH (redrawn from [32]) and b) at neutral pH and its 
cross-linking reaction with proteins (redrawn from [30]).  
1.3.2 Other cross-linking reagents 
A great number of chemical cross-linking reagents capable of reacting with the side 
chains of amino acids of proteins have been identified (for a thorough review, see [30]). 
However, in addition to glutaraldehyde, only a few of them have been used in the 
preparation of cross-linked protein crystals. Dialdehydes analogous to glutaraldehyde 
have been used to a minor extent. Margolin et al. [33] used succinaldehyde, glyoxal, and 
octanaldehyde to cross-link subtilisin crystals. However, the properties of these cross-
linked products were not reported in detail.  
Quiocho and Richards [5] studied the cross-linking of carboxypeptidase A crystals also 
with cross-linking reagents other than glutaraldehyde. Crystals cross-linked with 1,3-
difluoro-4,6-dinitrobenzene in resulted in insoluble crystals that were as active as 
glutaraldehyde cross-linked crystals. Also biphenyl-4,4’-bisdiazonium chloride was 
reported to cross-link carboxypeptidase crystals successfully, but no properties of the 
cross-linked crystals were provided. In their review Margolin and Navia [15] briefly 
described that they have used more than ten cross-linking agents. However, they don’t 
provide any information about what proteins they have cross-linked and the properties of 
the cross-linked products. Margolin and Navia [15] described also a reversible cross-
linking method. They modified Candida rugosa lipase (EC 3.1.1.3) by Traut’s reagent in 
order to introduce additional SH groups to the protein. Then the SH groups were further 
cross-linked with DPDPB. When the water-insoluble cross-linked product was incubated 
with exogenous cysteine, the crystals dissolved completely and released 85% of the 
initial lipase activity. 
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Margolin et al. [34] described the cross-linking of glycoprotein crystals based on 
chemical carbohydrate-to-carbohydrate cross-linking. Carbohydrates in glucose oxidase 
(EC 1.1.3.4) crystals were first oxidized by sodium periodate and then cross-linked by 
1,8-diaminooctane. Thereafter NaCHBH3 was used to reduce the imino groups in the 
product. The resulting cross-linked product was slightly soluble in water and exhibited 
specific activity similar to the soluble counterpart. These crystals were used to produce 
gluconic acid. Margolin et al. also prepared carbohydrate cross-linked crystals of C. 
rugosa lipase and several vaccine antigens.  
1.4 Porous structure of CLPCs 
In a crystalline form proteins are in a highly ordered three-dimensional array where the 
protein molecules are bound to each other with specific intermolecular interactions. 
Protein crystals contain not only protein molecules but also uniform solvent-filled pores 
that constitute 30–78% of the crystal volume [35, 36, 37] depending on the protein and 
the crystallization conditions. The solvent flows almost freely in the pores of crystalline 
proteins. Morozov et al. [38] measured that the self-diffusion coefficient of 
intracrystalline water in the tetragonal lysozyme crystals was reduced by about 30–40% 
compared with that of bulk water. Table 1 shows that the average diameter of the pores in 
cross-linked crystals varies between 25–80 Å, the porosity is 0.5–0.8, and the pore 
surface area is 600–1800 m2 g-1 depending on the protein in question. The pore surface 
area of cross-linked crystals is comparable with that of inorganic porous materials, such 
as zeolites, silica gels, and activated carbon [15]. The pore sizes in Table 1 have been 
calculated by using a cylindrical pore model and symmetrical pore distribution. However, 
the pores within protein crystals are complicated in structure and cannot, thus, be 
described by a simple cylindrical model [36, 39, 40]. Morozova et al. [40] presented that 
the pore size in cross-linked tetragonal lysozyme crystals varied between 6–40 Å 
measured from crystallographic data. Figure 2 illustrates the pore structure in a native 
xylanase (EC 3.2.1.8) crystal lattice. The pore sizes measured from crystallographic data 
[36, 38] are systematically smaller than presented in table 1.  
Table 1. Characteristics of CLPCs. 
Protein Solvent content Porosity 
Pore surface 
area (m2 g-1) 
Pore diameter 
(Å) Ref 
Thermolysin (EC 3.4.24.27) 50% 0.51 800 46 [36] 
Lipase (Pseudomonas 
cepacia) (EC 3.1.1.3) 74% 0.80 1800 82 [36] 
Lipase (C. rugosa) 49% 0.50 900 38 [36] 
Human serum albumin – 0.65 1500 54 [36] 
Xylose isomerase 41–53% 0.47 600 29 [39] 
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Figure 2. Crystal lattice structure of Trichoderma reesei xylanase II crystal. The solvent-filled channels are 
shown in black. The maximum cross section of the pore opening in the crystal is approximately 7×25 Å 
[41]. The surface representation was computed from 1.5 Å resolution X-ray diffraction data [42]. 
1.5 Activity of CLPCs 
In aqueous solvent the activity of cross-linked protein crystals is most often reduced 
compared with that of soluble proteins. Table 2 shows the activity of soluble proteins, 
crystalline proteins, and cross-linked crystalline proteins. As shown in the table the lower 
activity may a result from crystallinity or the chemical modification of proteins, or a 
combination of both.  
Mass-transfer limitations have been recognized in numerous publications to decrease the 
activity of CLPCs compared with the soluble counterparts. There are three factors 
affecting the mass-transfer limitations: the size of the crystalline particle [5, 15, 43], the 
size of the substrate [15, 17, 21, 36], and the pore size of the crystal. As shown above, the 
sizes of the open channels in protein crystals are 10–80 Å in diameter. As a consequence, 
large molecules having a molecular weight higher than 1000–10000 g mol-1, depending 
on the protein crystal in question, cannot penetrate the crystals at all [36, 39]. Smaller 
molecules can diffuse through the pores. However, the diffusion rate can be considerably 
decreased compared with the diffusion rate in water. The effective diffusion coefficients 
of surfactants (MW 246–316 g mol-1) inside tetragonal lysozyme crystals were 3–4 
orders of magnitude lower than those of the corresponding free molecules in water [44].
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Table 2. Activity of some cross-linked protein crystals (CLPC) compared to the activity of the protein in soluble or un-cross-linked crystalline form in aqueous solvent. Note 
that the units of activity are not comparable with each other as they are presented here in the same form as in the original publications. 
*shortest dimension; **N.D. = not determined 
      Activity
Protein    Reaction Soluble Crystalline Cross-linked crystals (CLPC) 
Crystal size* 
(µm) 
Activity ratio 
(VCLPC/Vsoluble) 
Ref 
Subtilisin  Hydrolysis of N-trans-cinnamoylimidazol       0.094 s-1 N.D. 0.115 s-1 <5 1.2 [18]
Subtilisin  Hydrolysis of TAME at pH 8.0 136 s-1 80 s-1 30 s-1 <5   
   
     
 
  
  
     
     
   
   
0.2 [18]
Subtilisin   Hydrolysis of N-acetyl- L-phenylalanine ethyl 
ester in 15% (NH4)2SO4
N.D.** 2.3 mmol  
min-1 mg-1
1.3 mmol  
min-1 mg-1
N.D. – [21]
Subtilisin   Hydrolysis of N-acetyl- L-phenylalanine ethyl 
ester in 0.1% NaCl 
10 mmol 
min-1 mg-1
N.D. 6 mmol
 min-1 mg-1
N.D. 0.6 [21]
Carboxypeptidase A Hydrolysis of carbobenzoxyglycyl-L-
phenylalanine 
140 ∆A570
min-1 mg-1
0.5 ∆A570 
 min-1 mg-1
0.3 ∆A570 
 min-1 mg-1
<5 2×10-3 [5] 
Carboxypeptidase A Hydrolysis of carbobenzoxyglycyl-L-
phenylalanine 
10000 min-1 N.D. 364 min-1 0.5 4×10-2 [43] 
Carboxypeptidase B (EC 3.4.17.2) Hydrolysis of benzoxyglycylarginine  3600 min-1 N.D. 220 min-1 1 6×10-2 [45] 
Lipase (C. antarctica) (EC 3.1.1.3) Hydrolysis of p-nitrophenyl butyrate 1 N.D. 0.013 <1 1×10-2 [46] 
Lipase (C. rugosa) Hydrolysis of chloroethyl ester of 2-(3-
benzoylphenyl)propionic acid  
1.2 mmol  
h-1 mg-1
N.D. 1.4 mmol
 h-1 mg-1
2 1.2 [47]
Thermolysin Hydrolysis of furylacryloylglycyl- L-leucine 
amide 
1 N.D. 0.8 N.D. 0.8 [48]
Chloroperoxidase Oxidation of thianthrene 555 s-1 N.D. 0.85 s-1 10 2×10-3 [19] 
Chloroperoxidase Oxidation of thioanisole 4170 s-1 N.D. 28 s-1 10 7×10-3 [19] 
Catalase (EC 1.11.1.6) Oxygen release from hydrogen peroxide 1 0.55 0.55 N.D. 0.6 [16] 
Fructose diphosphate aldolase (EC 
4.1.2.13) 
Synthesis of tagetitoxin  1 0.65 0.82 pulverized 0.8 [49] 
Lactate dehydrogenase (EC 
1.1.1.27) 
Lactate production from pyruvate 1 0.7 0.3 N.D. 0.3 [50] 
Morozova et al. [40] calculated that the mobility of cations was 4–50 fold lower and that 
of anions 100–300 fold lower in the tetragonal lysozyme crystals compared with the 
mobilities in solution. Even the self-diffusion coefficient of intracrystalline water in the 
tetragonal lysozyme crystal is reduced by about 30–40% compared to that of bulk water 
[38]. 
The crystal size plays a crucial role in the activity of the crystals. Most of the catalytic 
reactions are taking place inside the crystals, as even with very small crystals (e.g., 
1×1×2 µm3) more than 99% of the protein molecules are located in the interior of the 
crystal [15]. As a consequence, the substrate and the product have to diffuse from the 
bulk to the catalytic site and from the catalytic site to bulk solution, respectively. Table 3 
shows the relative activity of cross-linked crystalline enzymes in respect to the crystal 
size. The effect of the crystal size on the activity depends on the kinetics of the reaction, 
the size of the pores, and the size of the substrate and product [5, 15]. The crystal size has 
the most dramatic effect on reactions involving large molecules that can diffuse only 
partially or cannot diffuse at all to the pores of crystal [15, 17, 21, 36].   
Table 3. The effect of particle size on the relative activity of cross-linked protein crystals. 
Protein Particle size in the smallest dimension (µm) 
Relative activity*  (per 
unit weight of enzyme) Ref. 
Carboxypeptidase A  58 1 [5] 
 28 1.6  
 6 5.6  
Alcalase  40 1 [15] 
(EC 3.4.21.-) 1.2 3.2  
Penicillin acylase  142 1 [15] 
(EC 3.5.1.11) 57 3.4  
*Activity relative to the activity of the biggest crystals 
  
Limited conformational flexibility may cause dramatically reduced protein activities 
[51]. In the crystal lattice proteins have multiple specific intermolecular interactions. 
These interactions may stabilize proteins but can also reduce the flexibility of protein 
molecules. Another source of limited flexibility is the chemical cross-linking. In recent 
reports Ayala et al. [19] and Costes et al. [52] showed that the specific activity of cross-
linked crystals of chloroperoxidase and hydroxynitrile lyase (EC 4.1.2.37), respectively, 
decreased with increasing the glutaraldehyde concentration used in cross-linking. 
However, maximal stability and total insolubility was only achieved in conditions using 
high concentration of glutaraldehyde in both cases. Similar results were obtained with 
subtilisin [18]. However, Sobolov et al. [49] reported that the use of increasing amounts 
of glutaraldehyde increased also the specific activity of cross-linked fructose diphosphate 
aldolase crystals. The reason for this phenomenon is not known. 
However, the reduced protein flexibility caused by crystallization and cross-linking can 
also be exploited. Grochulski et al. [53, 54] showed that the properties of cross-linked C. 
rugosa lipase crystal preparations were affected by the conformation of lipase during 
crystallization and cross-linking. In lipase molecule there is a certain “lid” that is “open” 
enabling substrate binding to the active site when the active site is unoccupied. However, 
when the “lid” is “closed” the substrate is enclosed to the active site of lipase. If lipase 
was crystallized and cross-linked “lid open”, the activity was three times higher than if 
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crystallized “lid closed”. The crystallization and cross-linking of lipase in “lid open” 
form allowed a rapid binding of the substrate to the active site and a rapid removal of the 
product from the active site thus increasing the specific activity.  
In addition to the reduced flexibility the cross-linking can also have other effects on the 
activity of protein crystals. It is possible that glutaraldehyde cross-linking creates steric 
hindrances in the crystal lattice, which may occlude some active sites [51]. Chemical 
cross-linking may also modify catalytically important residues at or near the active site 
and, thus, affect the catalytic properties of the protein. 
1.6 Stability of cross-linked protein crystals 
The chemical cross-linking of protein crystals significantly enhances the stability against 
heat denaturation, proteolytic enzymes, and organic solvents compared with 
corresponding soluble proteins as shown in Table 4. The enhanced stability can be a 
result of crystallinity, chemical cross-linking of the proteins, or a combination of both. In 
the crystalline form proteins maintain better their native conformation in conditions that 
would lead to an unfolding of soluble protein [15]. This is a result of the highly ordered 
three-dimensional array of protein molecules in crystal where protein molecules are 
bound to each other with specific intermolecular interactions. The crystalline 
environment enhances the stability of proteins against heat and other denaturants by 
preventing unfolding, aggregation, or dissociation of proteins [15, 18, 30]. The chemical 
cross-linking is another source of stabilization. It has been shown that long 
glutaraldehyde cross-linking times yielding a high degree of cross-linking is needed to 
achieve maximal stability of cross-linked protein preparates [18, 19, 51]. It seems that 
cross-linked crystals are universally resistant to digestion by proteolytic enzymes [18, 20, 
23, 48, 55]. Possibly, proteases can, at least partly, digest the proteins locating on the 
protein crystal surface. However, these digested surface proteins remain attached to the 
surface of the crystal preventing the proteases to enter the crystals. Because only a small 
fraction of the protein molecules are located on the crystal surface, the activity of cross-
linked crystal remains at the initial level. 
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Table 4. Stability of soluble proteins and cross-linked protein crystals. 
 
  Half-life  
Protein Incubation conditions Soluble Cross-linked crystals Ref.
Stability at high temperatures    
Horse liver alcohol 
dehydrogenase (EC 
1.1.1.1) 
HEPES buffer, 30 °C, pH 8 14 d No loss in activity  
 after 3 months 
[56]
Subtilisin 55 °C, 0.1 M acetate, pH 5.7 2 h No loss in activity   
after 20 h 
[18]
Yeast alcohol 
dehydrogenase (EC 
1.1.1.1) 
40 °C, 0.1 M Tris-HCl buffer, pH 7 <1d No loss in activity 
 after 4 d 
[23]
Lactate 
dehydrogenase 
25 °C, 0.1 M phosphate buffer, pH 7.5 <4 d 10% loss in activity  
after 25 d 
[50]
Lipase 
(C. antarctica) 
40 °C, 0.02 M phosphate buffer, pH 7 <4 d No loss in activity  
after 6 d 
[46]
Lipase (C. rugosa) 40 °C, 0.01 M Tris-HCl buffer, pH 7 5 h >13 d [47]
Thermolysin 65 °C, Tris-HCl buffer, pH 7 6 h No loss in activity  
 after 5 d 
[48]
Xylose isomerase 77.5 °C, 45% (w/v) glucose/fructose 
solution, pH 7 
71 min 407 min [57]
Stability in the presence of proteolytic enzymes    
α-Chymotrypsin (EC 
3.4.21.1) 
5 mg ml-1 unspecific bacterial protease, 
0.1 M citrate buffer, pH 4 
4 min 11 h [23]
Thermolysin Mixture of Streptomyces griseus 
proteases, 65 °C, Tris-HCl buffer, pH 7 
<5 min 5% loss in activity  
after 4 d 
[48]
Stability in the presence of organic solvents    
Horse liver alcohol 
dehydrogenase 
90% 2-propanol, 25 °C <1 min 2 d [56]
α-Chymotrypsin 50% (v/v) dioxane, 0.1 M citrate buffer, 
pH 4 
0.5 h 2.3 h [23]
α-Chymotrypsin 50% (v/v) hexadecane, 0.1 M citrate 
buffer, pH 4 
16 h 3500 h [23]
Subtilisin Acetonitrile, 45 °C 5 d 200 d [58]
Subtilisin 50% acetone, 40 °C 4 d No loss in activity  
after 7 d 
[55]
Lipase (C. rugosa) 50% DMSO, 25 °C, 0.01 M Tris-HCl 
buffer, pH 7 
0.7 h 300 h [47]
1.7 Mechanical stability of CLPCs 
Native protein crystals are known to be fragile and they are easily cracked or chipped 
even by gentle mechanical forces. In contrast, cross-linked protein crystals are 
considerably more stable towards mechanical stresses than native crystals. The source of 
this mechanical stabilization is clearly the chemical cross-linking. Quite surprisingly, 
only Lye and co-workers have actually measured the mechanical stability of cross-linked 
protein crystals using C. rugosa lipase and yeast alcohol dehydrogenase as model 
crystals. Flat plate (thickness <2 µm) crystals of lipase [23] cross-linked in 0.5% 
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glutaraldehyde and yeast alcohol dehydrogenase [59] cross-linked in 0.05% 
glutaraldehyde remained intact in conditions equivalent to those expected in the high-
shear regions of stirred-tank reactors (εmax = 0.34 ×105 W kg-1). The native crystals of 
yeast alcohol dehydrogenase were significantly fragmented in the same conditions [59]. 
However, at high shear stress (εmax = 6.8 ×105 W kg-1) both lipase and yeast alcohol 
dehydrogenase crystals were broken, and the median crystal size was decreased from an 
initial value of 13 µm to 7 µm and 12 µm to 7 µm for lipase and yeast alcohol 
dehydrogenase, respectively [23, 59]. The lipase crystals that were cross-linked in 5% 
glutaraldehyde, and small cross-linked rod-shaped yeast alcohol dehydrogenase crystals 
having an average size of 5 µm, were totally resistant even to the high shear stress (εmax = 
6.8 ×105 W kg-1). The visual inspection of the broken crystals showed significant 
rounding of the crystal edges. This suggests that the mechanism of breakage is primarily 
a result of attrition by crystal-crystal collisions [59]. 
The mechanical integrity of cross-linked yeast alcohol dehydrogenase crystals was 
studied under compressive and abrasive forces found in dead-end filtration. The cake 
resistance was constant over five cycles of mixing and filtration at a pressure of 100 kPa 
indicating no breakage of the crystals. Rod-shaped crystals had a lower cake resistance 
than the hexagonal crystals. This was explained by the size and shape of the crystals. 
Rod-shaped crystals are cylindrical and allow more voidage within the cake. The 
hexagonal crystals are flat plates that can stack on each other forming a very dense cake 
increasing the cake resistance. As a conclusion, Vaghjiani et al. [23] stated that the 
control of the size and shape of the crystals is important in relation to the downstream 
processing of cross-linked crystal suspensions. 
1.8 Cross-linked enzyme crystals as catalysts 
The reason for the choice to use an enzyme in the form of cross-linked crystals is most 
often based on the stability of the cross-linked crystals in both aqueous and organic 
media. The stability is achieved without a considerable loss of specific activity. Cross-
linked crystals are insoluble throughout the production process. They are mechanically 
robust and can be easily removed from the reaction mixture by filtration or centrifugation 
and, thus, they can be recycled, which increases the productivity of the catalyst [e.g., 17, 
23, 47, 59, 60]. The purity of the catalyst leads to a high enantioselectivity of the reaction 
[55]. Cross-linked crystals are, in addition, an extremely stable storage formula compared 
to soluble enzymes, for example [16, 18, 48, 49, 50, 56]. Table 5 summarizes the 
catalytic applications where cross-linked enzyme crystals have been used. 
 19 
 
Table 5. Catalytic applications where cross-linked enzyme crystals have been used. 
Enzyme Reaction Ref. 
Subtilisin Synthesis of peptides and peptidomimetics [17, 55] 
Subtilisin Regioselective hydrolysis [55] 
Subtilisin Transesterification  [55] 
Subtilisin Catalysis in supercrirical fluids [61, 62, 63, 64] 
Thermolysin Synthesis of peptides [17] 
Lipase  Enantioselective ester hydrolysis [47, 60, 65] 
Lipase Enantioselective transesterification [65, 66] 
Lipase Enantioselective acylation [65] 
Hydroxynitrile lyase Asymmetric syntheses [52] 
Fructose diphosphate aldolase Synthesis of tagetitoxin [49] 
Xylose isomerase Carbohydrate conversions [68, 69] 
Xylanase Hydrolysis of xylo-oligomers [41] 
Alcohol dehydrogenase Reduction of ketones with cofactor regeneration [70] 
Lactate dehydrogenase Production of lactate [50] 
Organophosphorous hydrolase 
(EC 3.1.8.1) 
Hydrolysis of pesticide [71] 
 
1.8.1 Proteases 
The protease subtilisin is used in synthetic chemistry in both aqueous and organic 
solvents for regio- and enantiospecific reactions, amide bond syntheses, and hydrolyses. 
Two major problems have limited the use of subtilisin: low stability in water and water-
miscible solvents, and low activity in neat organic solvents [55]. The reason for low 
stability in water is the autodigestion, which reduces the half-life of the catalyst and 
makes the product purification difficult.  
Tüchsen and Ottesen [18] demonstrated that cross-linked subtilisin crystals were resistant 
to the autodigestion, which rapidly decreased the activity of soluble subtilisin in aqueous 
solvent. Wang et al. [55] showed that cross-linked subtilisin crystals retained full activity 
after 7 d incubation in aqueous buffer at 60 °C, 50% acetone at 40 °C, and in 70% DMF 
at 25 °C. Crude enzyme extract lost half of its activity after 11 h in aqueous buffer and 
after 4 d in 50% acetone. Cross-linked subtilisin crystals were highly active in various 
organic solvents. However, cross-linked crystals required a small amount of water in neat 
organic solvents, especially in a polar solvent such as acetone or DMF [55]. The total 
absence of water resulted in the loss of catalyst selectivity and ultimately in the complete 
loss of activity [55]. Xu and Klibanov [72] showed that the use of the cross-linked 
crystalline form of subtilisin in neat organic solvents enhances the enzyme activity 
compared with lyophilized subtilisin precipitate. The activity of lyophilized subtilisin in 
nonaqueous media is affected by the pH of the solution, where the lyophilization is 
conducted (so called “pH memory”). When lyophilized enzymes are suspended in non-
aqueous media, the protonation status of these groups does not change. In the case of 
cross-linked crystals, water can be removed by repeated washing with a water-miscible 
solvent. The solvent diffuses through the channels in the cross-linked crystals and the 
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interstitial water diffuses out. Since this occurs while there is still water present, the 
protonation state adjusts accordingly, as the protons are not kinetically trapped [72]. 
However, Montaneñez-Clemente et al. [73] showed that the activity of subtilisin 
Carlsberg was enhanced by lyophilization with methyl-β-cyclodextrin (MβCD). This 
method yielded a catalyst that was more active than cross-linked crystals of subtilisin. In 
all demonstrated reactions the MβCD-co-lyophilized enzyme was more active and as 
enantioselective as the cross-linked crystalline preparation. 
In the synthesis of peptides and peptidomimetics, the use of polar, water miscible organic 
solvents is useful since it improves the substrate solubility and shifts the equilibrium 
towards products [74,75,76]. Wang et al. [55] synthesized peptides with cross-linked 
subtilisin crystals. Acetonitrile containing 1% water was found to be the best solvent for 
the synthesis. In the same conditions the soluble enzyme was inactivated rapidly. Cross-
linked subtilisin crystals accepted both L- and D-amino acid amides as nucleophiles and 
showed a similar reaction rate for both enantiomers. One major benefit with the cross-
linked subtilisin crystals is the lack of autodigestion. A peptide synthesis catalyzed by 
soluble subtilisin leads to product purification problems as a result of the contaminating 
peptides produced by subtilisin autodigestion. Persichetti et al. [17] showed that cross-
linked thermolysin crystals catalyzed several peptide syntheses. The specific activities of 
soluble and cross-linked crystalline thermolysin were very close to each other. Also a 30 
amino acid peptide, an oxidized insulin B chain, was a suitable substrate for cross-linked 
thermolysin crystals with an initial rate of 4% of that observed for a soluble catalyst. 
However, in the cross-linked crystalline form thermolysin was considerably more stable 
than the soluble enzyme in ethyl acetate and in mixtures of water-miscible solvents 
(DMF, THF, acetone) and water [17]. St. Clair and Navia [48] also reported a greatly 
enhanced stability of thermolysin in the cross-linked crystalline form. 
Wang et al. [55] studied the regioselective hydrolysis of the terminal amide of peptide 
amides by cross-linked subtilisin crystals. The catalyst accepted a broad range of 
substrates and the reaction yields were quantitative. This hydrolysis method renders it 
possible to carry out the reactions in mild conditions. Normally harsh conditions are 
needed for regioselective hydrolysis leading to product racemication. Cross-linked 
subtilisin crystals have also been used for the hydrolysis of proteins, but they suffered 
from severe mass-transfer limitations of the high molecular weight substrates [18]. Wang 
et al. [55] used cross-linked subtilisin crystals also for a variety of reactions: 
enantioselective synthesis of a variety of molecules, regioselective reactions of many 
polyfunctional molecules, and for transesterification of amino acid and peptide esters. 
The cross-linked subtilisin catalyst was found to be excellent as a result of the high 
activity and stability in organic solvents, high regio- and enantioselectivity, and mild 
reaction conditions. The reusability of cross-linked subtilisin crystals was demonstrated 
by the resolution of a certain amine. After seven resolution cycles cross-linked crystals 
retained full activity without loss in enantioselectivity [55]. The crude enzyme extract 
lost 50% of its activity after two cycles. 
1.8.2 Lipases 
Lipases can be used for stereoselective ester conversions, regioselective and 
chemoselective acylations and deacylations, and simple hydrolysis of esters under mild 
reaction conditions [47]. Most often crude enzyme preparations have been used as 
biocatalysts because of their availability and low cost. However, crude lipase mixtures 
suffer from stability problems in organic solvents and they contain contaminating side 
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activities that have unexpected synthetic properties affecting the enzyme catalysis [47, 
77, 66, 65]. Lalonde et al. [47] identified competing hydrolase activities and protease 
activity in a crude extract of C. rugosa lipase. Cross-linked lipase crystals are 
considerably more stable in the presence of organic solvents than the soluble crude lipase 
preparations [46, 47, 77, 66, 65]. Neither cross-linked soluble lipase nor its precipitate 
lacking crystalline structure exhibit stability beyond the level of soluble enzyme [47]. 
Soluble pure lipases cannot be used in synthesis as a result of low stability against high 
temperatures and organic solvents [47, 78, 79]. The stabilization effect in organic 
solvents is extremely important, since many organic compounds are poorly soluble in an 
aqueous solvent. Both substrate specificity and enantioselectivity of cross-linked lipase 
crystals are markedly different from those of crude enzyme extract [47, 66, 65], which 
shows the benefit of using pure protein catalysts. In the preparation of cross-linked lipase 
crystals the enzyme is simultaneously purified in the crystallization. 
The use of cross-linked C. rugosa lipase crystals in organic solvents greatly improved 
enantioselectivities of several reactions including the resolution of acids by esterification 
[65], acylation of secondary alcohols with different carboxylic acids and with activated 
esters [65], and the ester hydrolysis [47]. The increased enantioselectivity was attributed 
to the purity of the protein. Persichetti et al. [65] showed that cross-linked lipase crystals 
were six orders of magnitude more active than lyophilized lipase in the resolution of 
menthol with vinyl butyrate in toluene [65]. Lalonde et al. conducted preparative 
resolutions (100 g scale) of methyl-Ibuprofen and Ketoprofen by cross-linked lipase [47]. 
The crystalline catalyst was recycled 18 times. During this time the specific activity 
dropped by 44%. However, immobilized lipase preparation lost virtually all of its activity 
after the first reaction cycle. Browne et al. [66] studied the production of inherently 
chiral calix[4]arenes by cross-linked crystals of lipases from Mucor miehei (EC 3.1.1.3) 
and Aspergillus niger (EC 3.1.1.3). The use of A. niger lipase in a cross-linked crystalline 
form improved the enantioselectivity of the reaction over chemical catalysis and free C. 
rugosa lipase catalysed synthesis.  
Collins et al. [60] reported the scale-up of chiral resolution using cross-linked crystalline 
lipase from Pseudomonas cepacia. The reaction studied was the chiral resolution of R-
sec-phenethyl alcohol from racemic R/S-sec-phenethyl acetate. The reaction parameters 
were first studied in small-scale (0.2–1 l) in order to determine the optimum conditions 
for a 100 l reactor. The reaction mixture contained two phases: aqueous phase and 
organic phase consisting of the substrate R/S-sec-phenethyl acetate. Cross-linked lipase 
catalyst was not detrimentally affected by a high shear in the reactor needed to obtain 
homogenous mixing in the two-phase system even in large-scale. In small-scale, the 
reaction yield was 48% and the product was formed with 99% enantiomeric excess. 
These values were not changed in the 100 l scale. A total number of nine runs were made 
with the same batch of cross-linked lipase crystals. In the first run, 50 g of crystals were 
added to the reaction mixture (0.5 g l-1). After nine runs about 12.5 g of lipase crystals 
were collected from the reactor. This decrease in the catalyst amount was a result of the 
problems in the catalyst recovery process after each run. Also the specific activity of the 
cross-linked catalyst decreased to one third of the initial value. 
In addition to catalytic applications, the cross-linked crystalline form of lipase can be 
used to determine the reaction kinetics and the parameters controlling the 
enantioselectivity in non-aqueous media, which cannot be studied by pure native 
enzymes as a result of their instability [65]. Cross-linked crystals are the only pure form 
stable and active enough for mechanistic studies [46, 47, 77, 66, 65].  
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1.8.3 Dehydrogenases 
The use of dehydrogenases in synthetic applications is often limited by the instability of 
both the enzymes and their nicotinamide cofactors [70]. St. Clair et al. [56] crystallized 
and glutaraldehyde cross-linked horse liver alcohol dehydrogenase (HLADH) in the 
presence of the reduced nicotinamide adenine dinucleotide (NADH), which was tightly 
bound to the enzyme by cross-linking. No leakage of cofactor from cross-linked horse 
liver alcohol dehydrogenase crystallized with NADH was detected in a prolonged 
incubation of concentrated protein crystal slurry. This was expected, as in the presence of 
the cofactor, horse liver alcohol dehydrogenase undergoes a large conformational change 
enclosing the cofactor [80] and, thus, preventing its dissociation from holoenzyme after 
crystals were cross-linked. Cross-linked crystals were active catalysts without any 
cofactor addition and catalyzed a reduction of several ketones. When HLADH was 
crystallized in the absence of NADH, the activity of the resulting cross-linked crystals 
was low even in the presence of exogenous NADH. The crystallization and cross-linking 
of HLADH in the presence of NADH greatly improved the stability of the enzyme and 
the cofactor. The half-lives of soluble HLADH and NADH were about 14 d and 3 d in a 
buffer solution at 30 °C, respectively. The cross-linked HLADH-NADH crystals 
maintained full activity after three months of incubation. Especially the stability of 
HLADH in the presence of organic solvents is important, because high concentrations of 
isopropanol, ethanol, and butanediol can be used for cofactor regeneration. The half-life 
of cross-linked HLADH-NADH crystals in 90% isopropanol was 2 d at 25 °C, for 
example. Soluble HLADH precipitated and lost activity immediately in these conditions. 
The cofactor recycle inside cross-linked HLADH-NADH crystals was demonstrated by 
the reduction of cinnamaldehyde in the presence of 200 mM of 1,4-butanediol to 
regenerate the cofactor. A column packed with approximately 50 mg of HLADH-NADH 
containing about 1.2 µmol NADH reduced 15 mmol cinnamaldehyde to cinnamyl 
alcohol.  
Sobolov et al. [50] studied the production of lactate from pyruvate in an electrolytic cell 
catalyzed by cross-linked lactate dehydrogenase crystals. The cross-linked crystalline 
form of the enzyme was used in the study solely because of the improved stability. 
Lactate dehydrogenase produces lactate from pyruvate and NADH. Only 10% of the 
activity of cross-linked crystalline lactate dehydrogenase was lost during 25 days of 
operation, while soluble lactate dehydrogenase lost its activity totally after 5 days. 
Furthermore, the cross-linked lactate dehydrogenase crystals could be recycled. The yield 
of lactate from pyruvate was 70% with cross-linked lactate dehydrogenase crystals. The 
yield with soluble enzyme was 50%, even though an aliquot containing the same amount 
of fresh enzyme that was present in the corresponding experiment in the form of cross-
linked crystals was added daily to the reaction mixture.  
1.8.4 Other enzymes 
Leisola and co-workers have studied cross-linked xylose isomerase (CLXIC) and 
xylanase crystals in packed bed reactors [41, 68, 69]. Because of the high enzyme to 
substrate ratio, they were able to identify new substrates for xylose isomerase (XI) [69]. 
They used a CLXIC reactor for isomerizations of a variety of pentose and hexose sugars 
[69], such as for the production of an unnatural sugar, L-ribose, from L-arabinose [69]. 
However, the reported efficiency of this conversion was low compared with chemical 
synthesis [81] or catalysis by a specific enzyme [82, 83]. They further showed that the 
packed bed reactor was capable of catalysis and simultaneous product separation [68]. 
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The reason for this was that each of the sugars (substrates and products) had a different 
reaction rate and binding characteristics to the CLXIC matrix. Similar product separation 
was observed in the hydrolysis of xylotetraose to xylose by cross-linked xylanase crystals 
in a packed-bed reactor [68].  
Sobolov et al. [49] characterized cross-linked fructose diphosphate aldolase crystals for 
the synthesis of tagetitoxin [67]. Soluble fructose diphosphate aldolase was an effective 
synthetic catalyst but suffered from instability, water insolubility of unnatural substrates, 
and high cost. However, the cross-linked crystalline form was highly stable without any 
observable loss of activity after 6 months of incubation in room temperature. In the same 
conditions the soluble enzyme lost its activity after 3–10 days. The specific activity of 
cross-linked crystals was 65% of the activity obtained with the soluble enzyme. In 
organic solvents (e.g., DMSO, acetonitrile, dioxane) the soluble form of fructose 
diphosphate aldolase lost 75–97% of the initial specific activity after 1 h incubation. 
However, with cross-linked crystals no significant loss of activity was observed. 
Hydroxynitrile lyase is used for asymmetric syntheses of intermediates for 
pharmaceuticals and agrochemicals. Hydroxynitrile lyase have been used both in soluble 
and carrier-immobilized forms. However, the stability of these enzyme preparations is 
relatively low both in aqueous and organic media [84, 85]. Costes et al. [52] prepared 
cross-linked hydroxynitrile lyase crystals and compared this with immobilized 
preparates. They used dry acetone in the cross-linking reaction in order to reduce the 
cross-linking time and glutaraldehyde concentration. They found that by increasing the 
concentration of glutaraldehyde in cross-linking the resulting crystals were more stable. 
The specific activity of cross-linked crystals was two orders of magnitude lower than the 
activity of Celite-immobilized hydroxynitrile lyase. However, the cross-linked crystals 
were much more stable in the presence of organic solvents. After seven one-hour 
reactions in a dibutyl ether solution, only 1% of the initial activity of Celite-immobilized 
enzyme was left. In contrast, more than 70% of the initial activity of the cross-linked 
crystals was retained in the same conditions. 
An organophosphorous hydrolase has been recognized to hydrolyze P–O, P–F, P–S, and 
P–CN bonds making a variety of chemical agents nonhazardous, including chemical 
warfare nerve gas VX [15, 71]. However, for practical applications the activity and 
stability has to be enhanced. Hoskin et al. [71] showed that cross-linked crystals of the 
organophosphorous hydrolase hydrolyzed the common pesticide Demeton-S. The authors 
assumpted that in the form of cross-linked crystals organophosphorous hydrolase could 
be economically used in practical applications. However, experimental data supporting 
this assumption was not shown. 
1.8.5 Enzyme catalysis in supercritical fluids 
Supercritical fluids (sc-fluids) are liquids that are heated under pressure until the vapor 
phase is as dense as the liquid phase. Sc-fluids have liquid-like densities and gas-like 
diffusivities. They are an environmentally friendly alternative to organic solvents for 
biocatalysis, because the solvent can be completely removed after depressurization. The 
most common sc-fluids are sc-CO2 and sc-ethane. Barreiros and co-workers have studied 
the properties of cross-linked subtilisin crystals in sc-fluids [61, 62, 63, 64]. The model 
system was cross-linked crystalline subtilisin catalyzing transesterification reactions. 
Cross-linked crystals in sc-ethane were 2–10-fold more active than in hexane or 
acetonitrile under similar conditions [61]. The specific activity of cross-linked crystals in 
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sc-ethane was 5–100-fold higher than the specific activity of lyophilized subtilisin. 
Especially with low water activities cross-linked crystals were superior [61]. The activity 
of cross-linked subtilisin was further enhanced by addition of salt hydrates [63] or 
zeolites [64] to the reaction media. This was probably a result of acid-base buffer effect 
of these additives in low water-activity media. The enzymatic catalysis by cross-linked 
crystalline enzymes in sc-carbon dioxide has been patented recently [86]. 
1.9 Cross-linked protein crystals as separation media 
Protein crystals have many properties that make them interesting separation matrices. 
They are made of L-amino acids that create an asymmetric environment. The interior of 
many globular proteins is hydrophobic. Several amino acid residues are either negatively 
or positively charged leading to ion exchange properties of proteins. Enzymes have also 
specific binding sites for their substrates and cofactors. In addition, protein crystals are 
microporous materials. 
Immobilized proteins have been used in chiral separations (for a review, see [87]). 
Vilenhick et al. [36] showed for the first time that cross-linked protein crystals can also 
be used in chiral separations. They described the chiral separations of phenylglycine and 
phenyllactic acid by cross-linked thermolysin crystals. These compounds are not 
substrates for thermolysin. Moreover, they showed that the cross-linked precipitate of 
human serum albumin did not separate the two enantiomers of folinic acid, while cross-
linked human serum albumin crystals gave good chiral resolution. This result suggests 
that the crystallinity is needed for good separation characteristics. The high surface area 
of crystalline proteins explained this result. Pastinen et al. [39] used cross-linked xylose 
isomerase crystals CLXIC in a chiral separation of a racemic mixture of D/L-arabitol. 
However, arabitol is also a substrate analog of the enzyme and the separation can be a 
result of the chiral nature of the protein, the specific binding of arabitol to the active site, 
or a combination of both. CLXIC showed also weak chiral separation ability for some 
D/L pairs of some amino acids [39]. 
CLXIC separated n-alcohols from C1 to C8 based on the hydrophobic interaction between 
the carbon chain of the alcohols and the protein [39]. The retention time of 1-octanol was 
approximately doubled compared with the retention time of methanol. CLXIC separated 
L-forms of tryptophane, histidine, tyrosine, and phenylalanine from other natural amino 
acids [39]. Vilenchik et al. [36] showed that cross-linked thermolysin crystals separated a 
mixture of Ibuprofen and phenyllactic acid. The mechanism of these separations is not 
known. 
Pastinen et al. [88] used CLXIC as an affinity separation matrix for sugar alcohols xylitol 
and sorbitol, which are substrate analogs to xylose isomerase. Sugar alcohols were 
specifically bound to CLXIC even from impure solutions, and were eluted by dilute 
CaCl2. Only the active form of the enzyme had the separation ability. However, only one 
molecule of xylitol or sorbitol was bound to each active center of xylose isomerase, 
which led to a low overall separation capacity of 1 g xylitol per 500 g CLXIC. 
Both Pastinen et al. [39] and Vilenchik et al. [36] pointed out the good mechanical 
stability of a cross-linked protein crystal stationary phase. A cross-linked xylose 
isomerase column was packed with 30 MPa pressure, and thermolysin and human serum 
albumin columns with 10 MPa pressure, which shows the rigidity of the crystals [36, 39]. 
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Vilenchik et al. [36] used a single column of both thermolysin and human serum albumin 
crystals for more than 500 injection cycles without any loss of separation efficiency. 
1.10 X-ray crystallography 
All protein crystals are sensitive to radiation used in X-ray crystallography, which is an 
essential tool in the structure determination of proteins. In some cases the crystal 
sensitivity is unmanageable and the diffraction quality of crystals deteriorates rapidly. 
Quiocho and Richards initially described the concept of cross-linked protein crystals in 
1964 [4]. They stabilized carboxypeptidase A crystals by glutaraldehyde treatment for X-
ray structure analysis. There are only minor changes in the diffraction pattern of cross-
linked protein crystals compared with that of the native crystals [4, 20, 21, 22]. Cross-
linked crystals render it possible to study the protein structure in organic solvents, which 
cannot be done with native crystals [21]. Recently Lusty [22] described the use of crystal 
cross-linking together with cryocrystallography, which is a common way to increase the 
stability of crystals towards the radiation. In cryocrystallography, crystals are treated with 
a cryoprotectant (e.g., sugar solutions, ethylene glycol, PEG, glycerol) and cooled rapidly 
to cryogenic temperatures (e.g., with nitrogen gas around 100 K). However, the crystals 
often suffer damage on cooling. Lusty showed that glutaraldehyde cross-linking 
protected the crystals from the damage on cooling without any effect on the diffraction 
properties. 
1.11 Design of new protein materials 
Dotan et al. [89] described the production of a pre-designed protein crystal lattice. They 
chose a nearly tetrahedral lectin concavalin A as a model building block. This lectin is a 
tetramer with a fully characterized three-dimensional structure. The lectin tetramer 
contains four binding sites for α-D-mannopyranoside or α-D-glucopyranoside. They used 
computer modeling, which suggested that the cross-linking of soluble lectin tetramers by 
bismannoside would result in the formation of a diamond-like three-dimensional protein 
lattice. Indeed, the addition of bismannopyranoside to the lectin solution resulted in a 
rapid formation of lectin crystals, which were simultaneously cross-linked. A chemical 
analysis of the bismannopyranoside content in the crystals supported the hypothesis that 
each lectin molecule was cross-linked through four molecules to its neighbors. The size 
of the resulting crystals was 0.1–100 µm depending on the pH in the crystallization. The 
cross-linked crystalline product was insoluble and resistant to pH changes. 
Häring and Shreier [90] combined the methods of chemical modification of the 
enzymatic framework as well as the enzymatic active site. First they prepared cross-
linked crystals of protease subtilisin. Then they activated the active site serine 221 by 
PMSF and subsequently PMSF was substituted by sodium hydrogen selenide. The 
selenol group was oxidized with hydrogen peroxide to yield a stable seleninic acid form 
of cross-linked subtilisin crystals. As a result, the semisynthetic seleno-subtilisin showed 
glutathione peroxidase activity, and catalyzed kinetic resolution of several racemic 
hydroperoxides. The preparation of seleno-subtilisin has been described earlier [91]. 
However, the crystalline seleno-subtilisin showed a high specific activity, and stability 
against organic solvents and high temperatures compared to amorphous seleno-subtilisin 
[90]. 
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1.12 Medical applications 
St. Clair et al. [92] investigated the possibility to use cross-linked protein crystals as 
antigens. Currently the progress is toward subunit vaccines, which are composed of a 
purified antigenic determinant separated from the disease-causing organism. To enhance 
the immune response, subunit vaccines universally require adjuvants and delivery 
vehicles. Human serum albumin in a cross-linked crystalline form showed up to 30-fold 
increased immunogenity and increased stability over the soluble albumin that was 
formulated with a commercial aluminium adjuvant. Additionally, Margolin et al. [34] 
crystallized and carbohydrate cross-linked several vaccine antigens to formulate 
vaccines. However, no details of the function of these antigens as vaccines were 
provided. 
Margolin and Navia described in their review [15] that cross-linked protein crystals could 
be used in oral lumenal therapy. Metabolic or gastrointestinal diseases are often the result 
of impaired or missing enzymes or protein function in the biochemical pathway. 
However, the conditions in the gastrointestinal track are challenging for protein drug 
delivery. The pH is acidic (pH < 2) and there is a high concentration of proteases in the 
stomach and gut. Because of the excellent stability and good activity of proteins in the 
cross-linked crystalline form, the patient can orally administer a cross-linked crystalline 
therapeutic protein to perform the desired reactions in the gut lumen. According to 
Margolin and Navia [15] preliminary results indicate that in a cross-linked crystalline 
form lipases are at least 100-fold more active and significantly more stable than 
commercial lipase products. These principles are also described in a recent patent 
application [93]. 
1.13 Biosensor applications 
De Mattos et al. [94] compared glucose biosensors prepared from commercial 
lyophilized glucose oxidase, crystalline glucose oxidase, and cross-linked crystalline 
glucose oxidase. The best performance in terms of sensitivity, detection limit, and 
operational stability was obtained with biosensors based on cross-linked protein crystal 
technology. Probably, the enzyme stability during immobilization, which includes drying 
the enzyme layer and contact between dried glucose oxidase and ethanol, is critical. The 
cross-linked crystals seemed more resistant to denaturation upon the preparation of the 
sensor. 
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2 Aims of the work 
Cross-linked protein crystals (CLPC’s) possess many excellent properties including high 
volumetric activity and stability. Thus, CLPC technology shows great potential as a 
novel protein formulation for use in various practical applications. The aim of this work 
was to study CLPC technology in bioseparation and biocatalytic applications. Two model 
systems were used in the study.  
An antibody Fab fragment ENA5His specifically recognizes one enantiomer of a racemic 
mixture of a chiral drug [95]. Previously, ENA5His has been used in a carrier-
immobilized form as an immunoaffinity chromatography material in order to prepare 
pure enantiomers from a synthetic racemic drug. However, the carrier-immobilized 
ENA5His suffered from poor stability in the presence of a high concentration of organic 
solvents needed to release the bound drug [95]. This means that simple carrier 
immobilization of ENA5His produces a workable but disposable separation matrix. The 
aim of the work with ENA5His was to stabilize the antibody molecule towards the harsh 
conditions used in the separation application and to develop a reusable immunoaffinity 
chromatography matrix by using CLPC technology. More specifically the aims were: 
• To create crystallization and cross-linking procedures for the production of a 
sufficient amount of active crystalline ENAHis material for immunoaffinity 
studies 
• To develop a reuseable immunoaffinity chromatography matrix for the separation 
of drug enantiomers  
Xylose isomerase (XI) is a widely used enzyme in industry as a result of its ability to 
catalyze the isomerization of D-glucose to D-fructose. Previously it has been shown that 
XI accepts all of the pentose sugars and many hexose sugars as isomerization substrates 
[96, 97, 98]. The aim of this study was to use cross-linked XI crystals to improve the 
production process of D-fructose or other sugars. More specifically the aims were: 
• To develop a crystallization process for the production of homogenous XI crystals 
of different size classes, which can be further used in cross-linked form for 
catalytic studies 
• To study reactions catalyzed by XI for the production of sugars 
• To investigate the possibility to use organic solvents in the sugar reactions 
catalyzed by cross-linked XI crystals to enhance the product yield 
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3 Materials and methods 
The materials and methods used in this study are described in detail in the original 
publications I–V. Here only essential materials and methods are briefly described. 
3.1 Antibody Fab fragment ENA5His 
3.1.1 Purification of ENA5His [I] 
The recombinant antibody Fab fragment ENA5His (molecular weight of 50.1 kD based 
on the amino acid sequence) was provided by VTT Biotechnology (Finland). The His-
tagged ENA5His was cloned and produced by Escherichia coli in a bioreactor as 
described by Nevanen et al. [95]. ENA5His was purified by metal-affinity 
chromatography. After a buffer change to 0.1 M Na-acetate buffer at pH 5.0, the purified 
Fab fragment was concentrated to 8 mg ml-1 by ultrafiltration and used further for 
crystallization. 
3.1.2 Crystallization and cross-linking of ENA5His [I] 
Vapor diffusion crystallization experiments were set up in hanging drops by the standard 
procedure. Batch crystallization was first set up in 0.2 ml scale in 0.5 ml Eppendorf tubes 
and then in 10 ml scale in 15 ml plastic test tubes in conditions derived from the hanging 
drop experiments. The ENA5His crystals produced in the batch crystallization were 
cross-linked by incubation in 0.5% (w/v) glutaraldehyde for 30 min.  
3.1.3 Preparation of native and cross-linked carrier-immobilized ENA5His [II] 
Chelating Sepharose Fast Flow (Amersham-Pharmacia, Sweden) was loaded with copper 
ions to prepare Cu-IMAC carrier. Sedimented carrier was mixed with ENA5His solution 
and the mixture was incubated for 30 minutes with a gentle mixing at 20 °C. The slurry 
was packed in a small glass capillary with an inner diameter of 2.5 mm. Cross-linked 
carrier-immobilized ENA5His was prepared by adding 1 ml of 0.5% glutaraldehyde 
solution in to the column at room temperature. The column was washed with fresh PBS 
(phosphate buffered saline) before further use. 
3.1.4 Drug racemate [I,II] 
Finrozole, 4-[3-(4-fluorophenyl)-2-hydroxy-1-(1,2,4-triazol-1-yl)-propyl]benzonitrile 
(C18H15FN4O), was provided by Hormos Medical Corp. (Finland). The two drug 
enantiomers studied are designated here as a and d. 
3.1.5 Immunoaffinity chromatography of the drug racemate [II] 
The immunoaffinity columns containing CLAC matrix, carrier-immobilized ENA5His, 
or cross-linked carrier-immobilized ENA5His were equilibrated with 20 bed volumes of 
PBS. Drug racemate (4 mg ml-1 in 100% DMSO) was diluted with 2% DMSO in PBS to 
the injection volume of 100 µl prior to the application into the column. The unbound 
drug enantiomer was washed from the column by 2% DMSO in PBS. The bound drug 
enantiomer was eluted by 60% methanol in PBS. The columns were operated by gravity. 
The drug enantiomers were analyzed from the fractions by HPLC.  
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3.2 Xylose isomerase (XI) 
3.2.1 Purification of XI [III, IV, V] 
D-xylose isomerase (XI) produced by a strain of Streptomyces rubiginosus was a courtesy 
from Genencor International Inc. (Hanko plant, Finland). The enzyme was diafiltered by 
a hollow-fiber ultrafiltration (MWCO 50 kDa) to 100-fold dilution with distilled water. 
After diafiltration, XI was purified by 3- or 4-fold crystallization from 0.76 M 
ammonium sulfate at pH 7.2 as described previously [99].  
3.2.2 Solubility of XI crystals [III] 
Wet XI crystals were washed into the desired salt solution by repeated centrifugation–
suspension cycles. The suspension containing XI crystals in a salt solution was incubated 
with a rocking mixer placed inside an incubator at a desired temperature. The soluble 
protein concentration was analyzed by measuring the absorbance of the liquid phase at 
280 nm.  
3.2.3 Crystallization of XI [III] 
Small-scale crystallization experiments were made in plastic test tubes. XI crystals were 
dialyzed against fresh water to dissolve the protein crystals and to remove the ammonium 
sulfate used in the purification of the protein. The protein concentration was adjusted to 
40 g l-1 by adding water. A proper amount of a concentrated salt solution was added to a 
4–8-ml aliquot of the protein solution to reach the desired final salt concentration. The 
solution was incubated with a rocking mixer placed inside an incubator at a desired 
temperature. The soluble protein concentration in the supernatant phase was analyzed 
measuring the absorbance of the liquid phase at 280 nm, and the presence of crystals was 
confirmed by light microscopy.  
Large-scale cooling crystallization experiments were made in 0.1–4.0-liter volumes. The 
protein concentration was adjusted to 40 g l-1. The XI solution was tempered to 28 °C in 
a water bath with impeller agitator using a stirring rate high enough for preventing 
sedimentation. Ammonium sulfate or magnesium sulfate was used for the crystallization. 
The temperature was lowered gradually to 4 °C.  
Uniform XI crystals were produced by cooling crystallization from 0.17 M magnesium 
sulfate. An appropriate amount of seed crystals was added with a stirring rate high 
enough for preventing sedimentation. The crystallization was continued at 25 °C until the 
soluble protein concentration was no more decreasing. After this, the temperature was 
lowered gradually to 5 °C within 48 h to maintain small supersaturation in the solution 
for preventing spontaneous nucleation but enabling the seed crystal growth. Seed crystals 
were prepared by crushing XI crystals through mixing them vigorously with glass beads 
(d = 3 mm) for 2 h. 
3.2.4 Cross-linking of XI crystals [V] 
XI crystals were cross-linked by glutaraldehyde and L-lysine hydrochloride. Cross-linked 
XI crystals (CLXIC) were stored at 4 °C in water.  
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3.2.5 Measurement of initial reaction rates catalyzed by CLXIC (unpublished) 
The measurements were conducted in a 100 ml batch reactor equipped with impeller 
agitator. The stirring rate was 100 rpm to exclude external mass-transfer limitations. All 
reactions were carried out in substrate solution containing 360 g l-1 D-fructose in Na-
HEPES buffer (pH 7.5) supplemented with 20 mM MgSO4. Adding about 50 mg of 
cross-linked XI crystals (CLXIC) to 50 ml of substrate solution initiated the 
isomerization reaction of D-fructose to D-glucose. The exact amount of the enzyme added 
to the reactor was measured afterwards. Samples of 1 ml were taken intermittently from 
the reaction mixture. The D-glucose concentration of the samples was measured by an 
enzymatic analyzer YSI 2700 (YSI Instruments, USA). Measurements were made at 
temperatures of 40 °C, 50 °C, 60 °C, and 67 °C. After the reaction, CLXIC was filtered 
from the reaction mixture and washed several times with reverse osmosis treated water. 
After vacuum drying for 24 h at 20 °C the crystal samples were weighed. The initial 
reaction rate (molglu gCLXIC-1 s-1) of D-fructose isomerization to D-glucose was calculated 
from samples where the conversion of the substrate was less than 5%. The initial reaction 
rates were measured for CLXIC of different size classes. All measurements were run in 
duplicates. 
The effective diffusivity of the isomerization reaction, De, was estimated from the 
experimental results assuming first-order kinetics. Thiele modulus, Φ, is given by: 
CD
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in which R is the radius of a spherical catalyst pellet, rideal is the ideal reaction rate 
obtained when mass transfer limitations can be excluded (moles product per mass of 
catalyst), ρc is the density of catalyst (1160 g 1-1 for CLXIC) [39], and C is the 
concentration of the substrate (2 mol l-1). XI crystal shape is polyhedral and, thus, very 
close to spherical. 
The value of Thiele modulus can be calculated from the internal effectiveness factor, η, 
which is given for spherical catalyst pellets and first-order kinetics by: 
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in which ractual is the actual reaction rate. 
3.2.6 C-2 epimerization reactions catalyzed by XI [IV] 
The reactions were carried out at 25–60 oC in 50 mM maleate buffer containing 20 mM 
MgSO4 at pH 7.2. Unless otherwise stated, substrate concentration in the reactions was 5 
mg ml-1 and soluble XI concentration was 1 mg ml-1. Adding the enzyme solution to the 
tempered substrate solution started the reaction. Adding 1 M sulphuric acid to lower the 
pH below 2 stopped the reaction. Some reactions were done with cross-linked XI crystals 
(CLXIC) packed in a 1.6 cm × 38 cm column. Sugar compositions were measured by 
HPLC. 
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3.2.7 XI catalysis in the presence of organic solvents [V] 
All the enzyme reactions were conducted in a 25 ml batch reactor equipped with impeller 
agitator. The reactions were carried out in a 50 mM maleate buffer (pH 7.2) containing 4 
mM Mg2+ or in a mixture of buffer solution and acetone or ethanol. The enzyme 
concentration was approximately 3 mg ml-1 and the exact amount of the enzyme was 
measured afterwards. The sugar composition of the samples was measured by GC. The 
initial rates of glucose isomerization (gfru gCLXIC-1 min-1) were determined from samples 
where the conversion of the starting sugar glucose was below 5%. 
The deactivation of XI was measured as follows. First XI was incubated in aqueous 
ethanol or acetone supplemented with 50 mg ml-1 D-glucose. After incubation for 24 h, 
XI was separated from the incubation medium by filtration (CLXIC) or by ultrafiltration 
(soluble XI) and washed with a fresh maleate buffer solution. Then the initial rate of 
isomerization with the washed enzyme was measured in pure aqueous maleate buffer 
containing 50 mg ml-1 D-glucose as the substrate. The sugar composition of the samples 
was measured by GC.  
4 Results and discussion 
4.1 Model system for bioseparation applications 
4.1.1 Crystallization of antibody fragment ENA5His [I] 
A preliminary screening of crystallization conditions for ENA5His was conducted 
employing hanging drop vapor diffusion experiments. After optimization good 
crystallization behavior was obtained in hanging drops containing 20–28% PEG 3350 
with 0.1–0.6 M KH2PO4 or NaH2PO4 at 5 °C and 20 °C. Figure 3a shows typical 
ENA5His crystals obtained in hanging drops. Harris et al. [100] were the first to describe 
the use of PEG 3350 in low ionic strength conditions for the crystallization of intact 
antibodies. Since then PEG 3350 has been used successfully in numerous crystallizations 
of antibodies and their fragments and, thus, it seems to be an especially useful 
crystallization agent for antibodies. Also in this work PEG 3350 proved to be the only 
precipitant producing ENA5His crystals. All the other precipitants including PEGs with 
molecular weights of 600, 4000, 6000, and 12000 failed to crystallize ENA5His.  
Once the conditions leading to good crystallization were identified by the hanging drop 
method, the crystallization was transferred to larger scale batch crystallization. A 10 ml 
crystallization batch containing 3.5 mg ml-1 protein, 20% PEG 3350 and 0.2 M NaH2PO4 
at pH 4.7 and 20 °C produced 25 mg of ENA5His crystals with a 70% yield. Figure 3b 
shows typical ENA5His crystals obtained in batch crystallization. Most of the crystals 
were relatively large being >50 µm in the smallest dimension but also small crystals and 
crystal fragments were present.The results obtained here together with the results of Lee 
et al. [101] show that a batch crystallization procedure can be relatively easily developed 
and scaled up based on crystallization conditions found by routinely used microdiffusion 
methods. Batch crystallization is the only realistic method for the production of protein 
crystals for practical applications. The ENA5His crystals produced in batch 
crystallization were cross-linked by the most commonly used protein cross-linking agent, 
glutaraldehyde. The resulting cross-linked antibody fragment crystals (CLAC) were 
insoluble in all the solutions that were used in the drug enantiomer separation 
application. This is a pre-requisite for the use of protein crystals in applications. 
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Figure 3. Crystals of an antibody Fab fragment ENA5His obtained a) by hanging drop method and b) in 
batch crystallization.  
4.1.2 Chiral separation of drug racemates by re-usable ENA5His columns [II] 
Immunoaffinity columns packed with cross-linked ENA5His crystals (CLAC) separated 
pure drug enantiomers from the racemic mixture. However, the large particle size of 
intact CLAC crystals (about 50×100×300 µm3) resulted in ineffective separation of the 
drug enantiomers probably as a result of mass-transfer limitations (publication [II], 
Figure 2). To enhance mass transfer, CLAC was crushed with glass beads to a size of 
about 1×5×20 µm3 or smaller. The crushing of CLAC considerably enhanced the 
separation of drug enantiomers. Figure 4 shows a typical drug separation chromatogram 
obtained with crushed CLAC. The drug d-enantiomer binding capacity was 2.3 µg per 1 
mg of crushed CLAC, which is about 35% of the theoretical binding capacity based on 
1:1 molar binding ratio. With carrier-immobilized ENA5His, the binding capacity 
corresponded to 70% of the theoretical binding capacity.  
Reduced enzyme activities of cross-linked enzyme crystals have been frequently reported 
in the literature. The reduced activities are usually explained either by mass-transfer 
limitations inside the crystals or by the reaction between the protein and the cross-linking 
reagent, which limits the flexibility of protein molecule [15]. In this case, mass-transfer 
limitations fail to explain the reduced binding capacity of CLAC, as the mass-transfer 
limitations were seen as prolonged binding and elution times when big crystals were 
used. The high specific binding activity of the cross-linked carrier-immobilized 
ENA5His column showed that the reaction between the immobilized antibody and 
glutaraldehyde did not reduce the binding capacity (publication [II], Table 1). One 
reasonable hypothesis for the reduced binding activity of CLAC is that the extreme 
closeness of the protein molecules in the crystalline structures could easily lead to steric 
hindrances keeping a certain amount of binding sites not available for substrate binding. 
However, the reason for the reduced binding capacity of CLAC remained unknown. 
CLAC was resistant to the denaturing effect of methanol. During and after 25 binding-
elution (with 60% methanol) cycles the binding capacity and elution profiles of an 
immunoaffinity CLAC column were unchanged. The improved protein stability obtained 
by the use of cross-linked protein crystal technology has been explained by the 
crystallinity of the material, the chemical modification of the protein, or a combination of 
both [15]. 
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Figure 4. Typical chiral separation chromatogram of a drug racemate by an immunoaffinity column 
packed with crushed CLAC. About 13 mg of crushed CLAC was packed in the column; 50 µg of drug 
racemate was injected to the column; the bound drug was eluted from the column by changing the eluent to 
60% methanol. 
Because of the outstanding stability of the CLAC column, the role of cross-linking in the 
stabilization of ENA5His was studied in more detail with carrier-immobilized ENA5His, 
which was glutaraldehyde cross-linked. Glutaraldehyde cross-linking stabilized also 
immobilized ENA5His. After five times repeated enantioseparation cycles no loss in the 
drug binding capacity was observed. This result shows that glutaraldehyde cross-linking 
alone was enough to stabilize the ENA5His molecule against 60% methanol needed in 
the elution of the antibody bound drug. The glutaraldehyde cross-linking had no effect on 
the maximal d-enantiomer binding capacity, which was statistically identical to the value 
measured with native immobilized ENA5His (publication [II], Table 1). Simple 
glutaraldehyde cross-linking of carrier-immobilized ENA5His produced a highly stable 
and active protein matrix capable of producing pure enantiomers of the chiral drug. 
4.2 Model system for biocatalytic applications 
4.2.1 Solubility and crystallization of XI [III] 
XI crystal solubility in ammonium sulfate solution followed the traditional salting-out 
behavior. The solubility decreased logarithmically when increasing the ionic strength in 
the solution (Figure 5a). Surprisingly, in a magnesium sulfate solution XI crystals had a 
solubility minimum at approximately 0.17 M MgSO4 (Figure 5b). The reason for the 
specific effect of Mg2+ is not known. The effect of cations on protein solubility has been 
considered to be small compared with the effect of anions [102, 103, 104]. However, 
recently Bénas et al. [105] showed that also cations have an important role in the 
solubility of lysozyme. 
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Figure 5. Solubility of XI crystals in a) ammonium sulfate solution, b) magnesium sulfate solution. 
XI crystal solubility in both ammonium sulfate and magnesium sulfate increased 
logarithmically when increasing the temperature (publication [III], Figure 3). The strong 
temperature dependency of the solubility of the XI suggested that XI could be 
crystallized effectively by simple cooling crystallization. Indeed, XI was crystallized 
from concentrated ammonium sulfate solution and from 0.17 M magnesium salt solutions 
using cooling crystallization. The crystalline protein yield in the cooling crystallizations 
was very high, always over 95%. Magnesium sulfate was chosen for further 
crystallization optimization since ammonium sulfate must be used in large amounts 
compared to the amount of magnesium sulfate. 
4.2.2 Preparation of uniform XI crystals (III) 
The crystals produced by spontaneous nucleation resulted in heterogeneous crystal sizes 
of 5–150 µm even if a very gentle temperature gradient was used. However, the control 
of the size and shape of enzyme crystals is critical to their application as catalysts [15, 
23]. Large uniform crystals are needed for catalytic applications and small uniform 
crystals for analytical/chromatographic applications [15]. A well-known method for the 
production of uniform crystals of small molecular weight compounds is the use of seed 
crystals in crystallization. However, no reports of such a technique being used in large-
scale batch crystallization of proteins are available in the literature.  
On the basis of the solubility study, we were able to develop a simple and reproducible 
procedure to prepare homogeneous XI crystals. The preparation of uniform XI crystals 
was based on cooling crystallization from 0.17 M MgSO4.  At 28 °C no spontaneous 
nucleation occurred in a 40 g l-1 XI solution supplemented with 0.17 M MgSO4. Seed 
crystals were added to this solution to initiate the crystallization process. The temperature 
of the crystallization was then lowered gradually to 5 °C within 48 h. During this time 
the seed crystals were grown to their final size. The crystalline protein yield was typically 
95–98%. As expected, the final crystal size was bigger when the amount of seeds was 
decreased. Figure 6 shows XI crystals of different sizes prepared by using crushed 
crystals as seeds.  
XI crystals were further cross-linked by glutaraldehyde and L-lysine for catalytic studies. 
The use of L-lysine was obligatory in obtaining insoluble crystals. When the cross-
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linking was made by glutaraldehyde alone, the crystals completely dissolved in water 
within 30 min at 60 °C. Cross-linked XI crystals (CLXIC) were insoluble apart from 
strong alkaline conditions. CLXIC dissolved in 0.1 M NaOH within 24 h at 30 °C. 
Previously it has been shown that CLXIC is more thermostable in the presence of 
Figure 6. Uniform XI crystals produced by see
are in the same scale. 
substrate than the soluble protein [57]. 
ding crystallization from 0.17 MgSO4. Note that the crystals 
line mass-transfer limitations (unpublished) 
ed XI crystals (CLXIC) 
ect of crystal size on the 
ata 
was in the range of (0.5–1.2)×10  m  s . This value was independent of the reaction 
4.2.3 Intracrystal
The initial D-fructose isomerization rate catalyzed by cross-link
of different crystal sizes was measured in order to study the eff
actual activity of CLXIC. Figure 7 shows that the actual activity of CLXIC decreased 
when increasing the crystal size. The reason for this is clearly the mass-transfer 
limitations inside the crystals. The activity of the smallest crystals having a particle size 
of <1 µm was even higher than the corresponding activity of the soluble enzyme. This 
result shows that the mass-transfer limitations can be excluded when these crystals are 
used. These results indicate that it would be reasonable to use the smallest crystals in 
applications in order to obtain maximal enzyme activity. However, small crystals are 
difficult to handle in practice. The removal of small particles is difficult from the reaction 
mixture, for example. However, from Figure 7 it can be seen that relatively high 
activities are obtained also with big crystals suitable for use in practical applications.  
The effective diffusivity of the isomerization reaction calculated from experimental d
-11 2 -1
temperature (40–67°C). The value of effective diffusivity is only estimation, as the 
assumption of first-order kinetics is inaccurate when high substrate concentrations are 
used. The reaction rate measurements were made at a high substrate concentration in 
order to discover the values of the overall effectiveness factor for different catalyst 
particle sizes in conditions close to those found in real processes. The calculated effective 
diffusivity was two orders of magnitude lower than the diffusivity of D-glucose or D-
fructose (molecular weight 180 g mol-1) in water at 25 °C [106]. The value of effective 
diffusivity was in good agreement with diffusivity values reported for lysozyme crystals. 
The diffusivities of fluorescent surfactants (molecular weight 246–316 g mol-1) inside 
tetragonal lysozyme crystals were 3–4 orders of magnitude lower compared with the 
diffusivities of corresponding free molecules in water [44]. The values of diffusivities 
were measured by following the penetration of light-emitting surfactants into the pores of 
lysozyme crystals. Morozova et al. [40] calculated that the mobility of cations was 4–50 
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fold lower and the mobility of anions 100–300 fold lower in the tetragonal lysozyme 
crystals compared with their mobility in solution. The calculation was based on the 
experimentally determined crystal conductivity and transference number of ions. 
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Lengthening the sugar carbon chain decreased the C-2 epimer formation rate roughly by 
D D
 At 
nd 
e activity of CLXIC decreases when increasing the crystal size. 
4.2.4 XI catalyzes a C-2 epimerization of sugars (IV) 
The reactions catalyzed by XI have been studied extensively. 
isomerization, it has been observed that also a C-2 
pentose and hexose substrates [97]. Nevertheless, in the most extensively studied 
isomerization of D-glucose to D-fructose, formation of the C-2 epimer (D-mannose) has 
not been observed previously. However, while studying D-glucose isomerization to D-
fructose catalyzed by a packed bed reactor containing CLXIC as the catalyst, in addition 
to D-fructose also D-mannose was detected from the out coming stream. This was a result 
of the extremely high enzyme to substrate ratio of the CLXIC column, which enables the 
detection of weak activities [68]. The finding of D-mannose, which is a C-2 epimer of D-
glucose, led to a more detailed study of the C-2 epimerization catalyzed by XI. Both D- 
and L-forms of tetrose (erythrose, erythrulose, threose), pentose (arabinose, ribulose, 
ribose) and hexose (glucose, fructose, mannose) sugars were chosen as the substrates.  
The C-2 epimer formation rate was highest with tetroses and lowest with hexose
one order of magnitude per one carbon atom. The C-2 epimer formation from D-mannose 
is an exception to this rule as a result of the fast isomerization rate between D-fructose 
(an isomer) and D-glucose (a C-2 epimer). The results of this study show that the real 
equilibrium in XI catalysed reactions is not between two isomers but between a ketose 
and its two aldose isomers. 
4.2.5 Acetone enhances CLXIC catalyzed -glucose isomerization to -fructose (V) 
Immobilized XI is used industrially for the conversion of D-glucose to D-fructose.
equilibrium at 60 °C, the isomerization reaction mixture contains 51% D-fructose a
49% D-glucose [107]. The thermodynamic equilibrium of the reaction favors D-fructose 
at high temperatures. In high fructose syrups used to sweeten soft drinks, for example, a 
D-fructose content of 55% is preferred to achieve the same sweetening effect as with 
sucrose and to prevent the crystallization of D-glucose [108]. However, the production of 
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a 55% D-fructose solution would require a continuous operation at 85–100 °C, which is 
too high a temperature for even the most thermostable XIs [109]. It has been shown 
previously that the addition of high concentration of ethanol favors the production of D-
fructose [110, 111]. However, as a result of the low productivity and poor stability of XI 
in the presence of ethanol, the use of ethanol was not applicable to real processes. 
The stability of CLXIC was studied in the presence of ethanol and acetone. After a 24-h 
treatment in 50% ethanol only 2% of the isomerase activity was retained. At the same 
se isomerization rates in pure aqueous solvent, 50% 
ethanol, and 50% acetone containing maleate buffer at different reaction temperatures 
Figure 8. Initial rate o r solvent, in 50% 
ethanol and in 
d in a linear manner when the acetone 
content in the reaction mixture was increased at 50 °C as seen in Figure 9. The initial D-
fructose production rate was more than doubled when high concentrations of acetone 
conditions the soluble enzyme lost its activity totally. However, the 24-h treatment 
decreased the activity of CLXIC only by 20–30% in solutions containing 10–90% 
acetone (publication [V], Figure 1). Surprisingly, acetone seems to have only a minor 
role in the inactivation of cross-linked crystals. The soluble enzyme was much more 
sensitive to acetone. In 50% acetone the activity of the soluble enzyme decreased by 
75%. This result shows that XI cannot be used in high ethanol concentration at relevant 
isomerization temperature. By contrast, XI in the form of CLXIC was stable even at very 
high acetone concentrations. 
Figure 8 shows the initial D-gluco
when CLXIC was used as the catalyst. The reaction rate in 50% ethanol was similar to 
that in pure aqueous solvent, except at the highest temperature (50 oC) measured, where 
the reaction rate was clearly smaller in ethanol containing solvent as a result of the 
inactivation of CLXIC. In 50% acetone the reaction rate was more than doubled 
compared with the rate in pure aqueous solvent at all temperatures. A higher temperature 
could not be used, as the boiling point of acetone is 56.5 °C at atmospheric pressure. 
Excluding the highest temperature with ethanol the activation energy of 59±2 kJ mol-1 for 
the isomerization reaction can be calculated from the slopes in Figure 8. The activation 
energy is not affected by the addition of organic solvents. This shows that the addition of 
organic solvent does not have an effect on the active site of XI.  
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were used. A higher concentration than 70% acetone could not be used as a result of the 
low solubility of D-glucose. No similar effect with ethanol was observed, as the initial D-
fructose production rate was lower than the rate in buffer solution. The increased activity 
of CLXIC can be partly explained by a shift in the concentration of the α-pyranose form 
of D-glucose present in the solution. In water, about 39% of the soluble D-glucose is 
present as α-pyranose. However, the α-pyranose content increased exponentially when 
the acetone content was increased (publication [V], Figure 3). In 90% acetone, the α-
pyranose content was 46%. The active center of XI accepts only α-pyranose form of D-
glucose as the substrate [112]. Lee and Hong [113] measured a 43% increased initial 
isomerization rate with pure α-D-glucose compared with buffer equilibrated glucose. 
Thus, the difference in the glucose composition accounts for the increased reaction rate 
only partly.   
The addition of acetone to the isomerization reaction mixture increased the concentration 
of D-fructose at the equilibrium in an exponential manner (publication [V], Figure 2). At 
equilibrium at 50 °C in buffer solution the reaction mixture contained 49±1% D-fructose. 
etone in the isomerization of D-glucose to D-fructose was beneficial in 
two ways, by increasing the reaction rate and the product yield. However, D-glucose is 
Figure 9. The effect ion at 50 oC. 
Protein crystallization is widely considered troublesome because of the often assumed 
unpredictability and irreproducibility of crystallization. However, the data presented in 
this thesis show that protein crystallization procedures can be developed systematically. 
The starting point for the crystallization development for xylose isomerase and the 
antibody Fab fragment ENA5His was quite different. Xylose isomerase is a widely used 
However, in 90% acetone the equilibrium D-fructose concentration was 63±1%. The 
reason for this increase may be the increase of the α-pyranose form of D-glucose in 
acetone solutions. 
As a conclusion CLXIC is stable even in high acetone concentrations. The use of a high 
concentration of ac
poorly soluble in acetone and, thus, high acetone concentrations (>70%) cannot be used 
in practical applications.  
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enzyme that was available 
crystal cross-linking, and biocatalytic ap
in kilogram quantities for the development of crystallization, 
plications. The crystallization process 
enabled the use of both studied 
e activity of small crushed XI 
ass transfer limitations. However, crystallization and cross-linking 
eparation application. The results of this thesis show that 
development for xylose isomerase was based on a systematic solubility study. Based on 
the results of the solubility study, a crystallization procedure yielding homogeneous 
xylose isomerase crystals with a high crystal yield was developed.  
The antibody Fab fragment ENA5His was only produced for research purposes in 
milligram scale. Thus, crystallization conditions had to be screened by using small-scale 
vapor diffusion experiments consuming only small amounts of ENA5His. The initial 
crystallization conditions found were analogous to conditions previously reported to be 
especially suitable for antibodies. The scale-up of the crystallization of ENA5His 
employing batch crystallization was straightforward.  
The results showed that the common cross-linking agent, glutaraldehyde, worked well in 
practice. ENA5His crystals became insoluble after glutaraldehyde treatment. However, 
the addition of L-lysine to the glutaraldehyde cross-linking reaction mixture was needed 
to obtain an insoluble form of cross-linked XI crystals.  
The cross-linking increased the stabilities of ENA5His and XI towards the denaturing 
effects of organic solvents. The improved stability 
proteins effectively in applications, where high concentrations of organic solvents were 
needed. 
Crystallization and cross-linking affected the activity of the protein samples. When the 
mass transfer limitation was excluded by studying th
crystals, the specific activity of XI remained at the same level compared with the activity 
of soluble XI. However, when bigger XI crystals were used the activity decreased as a 
result of intracrystalline mass transfer limitations. Also cross-linked crystals of ENA5His 
suffered from mass transfer limitations. Decreasing the crystal size by crushing decreased 
the effects of the m
decreased the specific drug binding activity of ENA5His by about 50% compared with 
carrier immobilized ENA5His. 
As a result of the stability and high activity of cross-linked XI crystals new reactions 
catalyzed by XI were found. Furthermore, the increased stability of the cross-linked 
crystalline form enabled addition of acetone to XI catalyzed D-fructose production from 
D-glucose, which increased the reaction rate and the product yield. 
The increased stability of ENA5His in cross-linked crystalline form enabled the reuse of 
ENA5His in the drug racemate s
the source of the increased stability was the chemical cross-linking by glutaraldehyde 
shown by the high stability of cross-linked immobilized ENA5His column. Cross-linking 
of immobilized protein column is a simple and economic process and, thus, very 
attractive way to increase the stability of proteins. 
The results of this thesis together with the results obtained previously show that cross-
linked protein crystal technology can improve the applicability of proteins. Especially, 
the regularly increased stability may open new applications for proteins using cross-
linked protein crystal technology. Moreover, the results show that cross-linked protein 
crystal materials can be designed systematically. Still, a future challenge is to apply the 
cross-linked protein crystal technology to commercial applications. 
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